A Market Opportunity Built on Existing Treatment Demand
Acute ischemic stroke represents an established pharmaceutical treatment market in China, with commercially available injectable and non-injectable therapies.
However, no single administration route is ideally suited to every patient.
Stroke-related swallowing difficulties, impaired tongue coordination, and oral-motor limitations can create challenges for certain patients using conventional dosage forms.
These administration challenges provide a potential point of differentiation within existing treatment pathways.
For BM Pharma, this is a strategic entry point — not the limit of the program's commercial ambition.
The Product Development Opportunity
BM Pharma is advancing an early-stage, differentiated non-injectable drug formulation program for acute ischemic stroke.
Our strategy focuses on three complementary development opportunities.
1. A Focused Clinical Entry Point
Investigating an alternative administration approach for selected patients who may experience difficulties with conventional oral or sublingual administration.
2. Broader Competitive Potential
Exploring a differentiated treatment option for a wider, clinically eligible ischemic stroke population, with the long-term objective of competing within established pharmaceutical treatment markets.
Broader adoption will depend on demonstrated efficacy, safety, drug exposure, administration performance, and clinically meaningful value compared with available options.
3. Continuity Across Treatment Settings
Evaluating a treatment pathway that could begin early during hospital-based care and, where clinically appropriate and supported by evidence, continue beyond hospital discharge to complete a prescribed treatment course.
This approach remains subject to validation of the treatment window, dosing regimen, safety, and clinical benefit.
Development Progress
Initial formulation development and exploratory animal pharmacokinetic studies have been completed.
Ongoing development focuses on formulation optimization, comparative drug exposure, administration feasibility, and preclinical safety evaluation.
The next phase is intended to generate evidence supporting candidate selection, clinical development strategy, and meaningful product differentiation.
Why Partner Early?
This program offers pharmaceutical companies an opportunity to participate in the development of a differentiated product within an established therapeutic market.
Potential partners can contribute to shaping the development pathway while managing investment exposure through predefined technical and scientific milestones.
Collaboration opportunities include funded feasibility evaluation, milestone-driven co-development, and potential technology licensing and regional commercialization partnerships.
Explore a Partnership
Early-stage investigational program. Clinical efficacy, safety, comparative advantage, suitability for home administration, and broad patient applicability have not been established. The program is not intended to replace emergency reperfusion treatment.
